Consensus Statement Issued for Low-Dose Oral Minoxidil for Hair Loss
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 21, 2024 -- Consensus has been reached for 76 items relating to low-dose oral minoxidil (LDOM) treatment for patients with hair loss, according to a statement published online Nov. 20 in JAMA Dermatology.
Yagiz Matthew Akiska, from the George Washington University School of Medicine & Health Sciences in Washington, D.C., and colleagues created an expert consensus statement for LDOM prescribing for patients with hair loss. Forty-three hair loss specialist dermatologists from 12 countries participated in a modified Delphi process, which started with 180 items in the first round.
Seventy-six items achieved consensus, which was reached if at least 70 percent agreed or strongly agreed. The authors noted that these items included diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM versus topical minoxidil, dosing for adults and adolescents, contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Consensus was not achieved for pediatric use and dosing items for children younger than 12 years or for LDOM titration protocols.
"This consensus statement contributes substantially to the current understanding of LDOM prescribing for patients with hair loss, providing a solid foundation for clinical practice," the authors write. "These consensus recommendations serve as a crucial reference for dermatologists treating patients with hair loss, offering best-practice insights into LDOM prescribing until further data emerge."
Several authors disclosed ties to the pharmaceutical, skin care, and medical technology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Public Believes Dermatologic Side Effects From Cancer Treatment Are Common
TUESDAY, Aug. 12, 2025 -- Most individuals living in underserved communities believe that dermatologic side effects (DSEs) from anticancer therapies (ACTs) occur at high rates...
Alopecia Areata Associated With Severe Psychosocial Impact
THURSDAY, July 24, 2025 -- Alopecia areata (AA) has a severe psychosocial impact, which is linked to illness perceptions and stigma more strongly than disease severity, according...
Prevalence, Incidence of Eczema Increase With Severity of Alopecia Areata
MONDAY, July 14, 2025 -- Patients with higher-severity alopecia areata (AA) have a higher prevalence and incidence of comorbid atopic dermatitis (AD), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.